GenSight Biologics S.A. (EPA:SIGHT)

Market Cap	19.59M
Revenue (ttm)	2.63M
Net Income (ttm)	-14.00M
Shares Out	154.27M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	504,708
Average Volume	638,890
Open	0.1308
Previous Close	0.1270
Day's Range	0.1264 - 0.1350
52-Week Range	0.1200 - 0.4960
Beta	1.96
RSI	37.15
Earnings Date	Sep 19, 2025

About GenSight Biologics

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 16
• Stock Exchange: Euronext Paris
• Ticker Symbol: SIGHT

Financial Performance

In 2024, GenSight Biologics's revenue was 2.63 million, a decrease of -11.44% compared to the previous year's 2.96 million. Losses were -14.00 million, -46.60% less than in 2023.